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Abstract
Background: Although much has been written about the influence of local opinion leaders on
clinical practice, there have been few controlled studies of their effect, and almost none have
attempted to change prescribing in the community for chronic conditions such as heart failure (HF)
or ischemic heart disease (IHD). These two conditions are common and there is very good
evidence about how to best prevent morbidity and mortality – and good evidence that quality of
care is, in general, suboptimal. Practice audits have demonstrated that about one-half of eligible HF
patients are prescribed ACE inhibitors (with fewer still reaching appropriate target doses) and less
than one-third of patients with established IHD are prescribed statins (with many fewer reaching
recommended cholesterol targets). It is apparent that interventions to improve quality of
prescribing are urgently needed. We hypothesized that an intervention that consisted of patient-
specific one-page evidence summaries, generated and then endorsed by local opinion leaders,
would be able to change prescribing practices of community-based primary care physicians.
Methods (study design): A pragmatic single-centre cluster randomized controlled trial
comparing an opinion leader-based intervention to usual care for patients with HF or IHD.
Randomization will be clustered at the level of the primary care physician; as the design effect is
anticipated to be negligible, the unit of analysis will be the patient. Patients with HF or IHD (not
receiving ACE inhibitors or statins, respectively) will be recruited from community pharmacies and
allocated to intervention or usual care based on the randomization status of their primary care
physician. The primary outcome is improvement in prescription of proven efficacious therapies for
HF (ACE inhibitors) or IHD (statins) within 6 months of the intervention.
Conclusion: If the methods used in this intervention are found to improve prescribing practices,
similar interventions could be designed for other chronic conditions dealt with in the outpatient
setting.
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Background
Opinion leaders – an untapped resource for quality 
improvement
Local opinion leaders are able to influence the practice of
other physicians because they are well-known, respected,
and trusted to evaluate medical innovations within the
local context [1-4]. Because they influence patterns of
practice in the community, and may accelerate the uptake
of knowledge, their participation in any program of qual-
ity improvement is essential. Certainly, surveys of physi-
cians [5,6] have consistently confirmed the importance of
colleagues and local consultants on individual patterns of
practice. Yet, the use of local opinion leaders to influence
physician practice has only been tested in six randomized
controlled trials [1,2]. While two of these trials [3,4] dem-
onstrated an important impact upon practice, both
assessed labour-intensive, expensive, hospital-based edu-
cational interventions spearheaded by a small number of
opinion leaders (four in one study, 16 in the other) for
conditions treated in a hospital setting (delivery by cesar-
ean section, treatment of acute myocardial infarction).
Although the use of opinion leaders to influence the out-
patient management of common conditions holds great
promise, this is yet a hypothesis to be rigorously tested
[7].
Underuse of proven medications for cardiac diseases is 
common
In fact, most patients with chronic conditions (such as
heart failure [HF] or atherosclerotic ischemic heart disease
[IHD]) are treated as outpatients. Previous practice audits
have documented significant "care gaps" between the
available evidence and actual practice (e.g., only half of
eligible patients with HF receive an ACE inhibitor [7,8],
despite overwhelming evidence of benefit [7,8], and those
who are prescribed an ACE inhibitor are usually given
doses below those tested in clinical trials [10]; less than a
third of patients with established IHD receive lipid-lower-
ing therapy [7,10,11], despite multiple trials [7,12,14]
showing benefit, and of those prescribed lipid-lowering
therapies, only 15% achieve recommended cholesterol
goals [11]). As these two conditions represent an impor-
tant burden of illness for the community [15], closure of
these care gaps should be a public health priority. Moreo-
ver, we believe methods need to be developed that can
reliably and efficiently improve the quality of care for
these high-risk populations [7].
Community-based interventions must be simple and 
practical
When testing the effect of opinion leader influence in the
outpatient setting, we must keep in mind the potential
generalizability and applicability of any proposed inter-
vention. Thus, the focus must be on a practical means of
incorporating opinion leaders into practice, because we
know that opinion leaders may exert considerable influ-
ence on community practice. In addition, previous studies
have established that the methods of information transfer
most favoured by physicians are one-page summaries of
guidelines or evidence [5,17]. Moreover, other work has
suggested that when the transfer of clinically relevant
information is directly linked to a specific patient encoun-
ter with a specific recommendation (e.g., real-time
reminders, whether manual or computerized) there is a
much greater likelihood of affecting change [2,7,18]. The
ideal way to create such a scenario would be to have a
"real-time" reminder generated in the physicians' office
and linked to the actual clinical encounter. This is not cur-
rently practical or feasible within the vast majority of com-
munity practices in Canada – most of these practices are
still paper-chart based, and even of those practices that
have electronic medical records and some capacity for
computerized decision support, most are not linked to
other databases such as vital statistics, hospital discharge
databases, or pharmacy dispensing records.
Potential role of community pharmacies and pharmacists
Prior research, and our own ongoing work in other clini-
cal arenas, leads us to believe that the community phar-
macy may be a reasonable location to generate the
requisite linkages needed to undertake an intervention to
improve quality of outpatient prescribing as well as a con-
venient site for unobtrusively recruiting patients [19]. This
is because patients with chronic conditions can be identi-
fied by "marker medications" at the time of presentation
to their pharmacy (more than 90% of HF patients are pre-
scribed loop diuretics [8], and almost 100% of patients
with known IHD are given prescriptions for short-acting
nitrates [20]), and because pharmacists already interact
on a regular basis with both prescribing physicians and
their patients. Therefore, the community pharmacy may
serve as a potential site for patient recruitment and educa-
tion or intervention. For example, the SCRIP study used
54 community pharmacies in Western Canada, and dem-
onstrated improvements in lipid management in a 675
patient randomized trial [19]. This pharmacy network has
evolved and expanded to bring together community phar-
macists, physicians and other healthcare professionals
into broad-based community-level studies through The
Epidemiology Coordinating and Research (EPICORE)
Centre and its subsidiary, the Centre for Community
Pharmacy Research and Interdisciplinary Strategies
(COMPRIS) at The University of Alberta.
Evidence-based interventions to improve quality of 
prescribing
With these basic considerations in mind, we designed an
evidence-based multi-faceted intervention to improve the
quality of prescribing in the community. We propose hav-
ing locally-nominated opinion leaders generate andBMC Cardiovascular Disorders 2005, 5:17 http://www.biomedcentral.com/1471-2261/5/17
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endorse one-page evidence summaries for two common
and chronic cardiovascular conditions. These evidence
summaries, linked with specific patient-level medication
profiles (generated at the community pharmacy), will be
distributed to practicing physicians and attached to their
patients' chart. Our hypothesis is that this will act as both
a source of credible and convincing information and a
specific reminder for action at the next patient encounter.
Our study is designed to test this hypothesis, by assessing
the impact of this intervention on the quality of prescrib-
ing for patients with heart failure or ischemic heart dis-
ease.
Methods
Purpose
The purpose of this study is to determine whether "evi-
dence summaries," generated and endorsed by local opin-
ion leaders, can improve the prescribing of proven
efficacious therapies by primary care physicians for their
patients with chronic cardiovascular diseases.
Objectives
This study has three main objectives:
1. To determine whether evidence summaries generated
and endorsed by local opinion leaders can increase the
prescription of efficacious therapies for patients with HF
or IHD.
2. To compare the effectiveness of the proposed interven-
tion with two different conditions, to begin to understand
the potential for generalizability across different diseases
and conditions.
3. To evaluate whether distribution of local opinion
leader endorsed evidence summaries, through commu-
nity pharmacies, is a viable quality improvement tool
within the constraints of current healthcare delivery sys-
tems.
Study design
A single centre pragmatic cluster randomized controlled
trial in which primary care physicians and their patients
will be randomly allocated to intervention (relevant sin-
gle page evidence summary endorsed by local opinion
leaders and a copy of the patient's current medication pro-
file faxed back to the primary care physician) or control
(only the patient's current medication profile faxed back
to the primary care physician). To prevent the potential
for "contamination" within an individual physicians'
practice (e.g., allocation of an intervention and a control
patient to the same physician) a modified form of cluster
allocation will be undertaken. Specifically, if a physician
is randomized to the intervention arm for IHD, her other
IHD patients that present to a participating pharmacy will
also be subject to the IHD intervention, to a maximum of
five patients. In addition, she will also act as her own con-
trol, because she will be assigned to the control arm for
her HF patients, again to a maximum of five patients. For
a schematic of the overall study design, please see Addi-
tional File: 1.
Identifying opinion leaders and generating evidence 
summaries
All primary care physicians within Capital Health (the
greater Edmonton metropolitan area, Alberta, Canada)
were mailed a one-page survey (based on a previously val-
idated opinion leader nomination instrument [3,4,21])
asking them to nominate local colleagues who best match
standard descriptions of "educationally influential" opin-
ion leaders (see Additional File: 2). The overall response
rate was 30% (225 of 788 surveys returned), typical of the
response rates for physician surveys. Five opinion leaders
were overwhelmingly identified by their peers (1 physi-
cian for HF only, 1 physician for IHD only, and 3 physi-
cians nominated for both HF and IHD; 3 opinion leaders
were cardiologists and 2 were general internists) and were
approached to participate in the development of the one-
page evidence summaries for HF and for IHD. All 5 nom-
inated opinion leaders participated in the development of
the intervention materials. The survey instrument also
informed primary care physicians about the study (in gen-
eral terms) and provided them the option to "opt-out" of
having themselves or their patients recruited or enrolled
in the study – only 19 physician respondents declined to
participate. Physician survey non-respondents (i.e., those
who did not explicitly and actively opt-out of the study)
will be considered eligible for the study, although any
physician will be able to withdraw themselves and their
patients at any time.
The data for the evidence summaries will be initially gen-
erated by experts in evidence-based medicine and cardio-
vascular care using standardized techniques for research
synthesis [22]; the opinion leaders and study investigators
will then ensure that treatment recommendations are
consistent with available clinical practice guidelines, and
then carefully incorporate this material into the one-page
evidence summaries. The final content and format of
these summaries will be arrived at by standard consensus
methods, and these evidence summaries will form the
core of our intervention.
Description of the intervention
The intervention consists of a disease-specific and patient-
specific one-page evidence summary. It will be a patient-
specific letter addressed to the patients' primary care phy-
sician, along with a description of the potential risks of
undertreatment and current evidence-based treatment rec-
ommendations. The letter will be signed and endorsed byBMC Cardiovascular Disorders 2005, 5:17 http://www.biomedcentral.com/1471-2261/5/17
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all 5 of the study opinion leaders. Examples of the IHD
and HF letters are provided in Additional Files: 3 and 4.
Accompanying the letter will be the most recent pharmacy
record of medications dispensed to the study patient. It is
intended that the evidence summary and the pharmacy
medication profile will become part of the patients' med-
ical record and act as a reminder or prompt at the next
patient visit. These materials will be faxed to the primary
care physician from the patients' community pharmacy.
Controls ("usual care")
Physicians of control patients will only receive the phar-
macy medication dispensing record. This will be done for
two reasons. First, to disentangle the effects of having a
complete medication record (in and of itself, a departure
from "usual care") versus the impact of the evidence sum-
maries. Second, to control for the possibility of any atten-
tion-related or study-related "Hawthorne effects" – all
patients and all physicians will receive the same number
of contacts and follow-ups, and all that will differ between
the experimental arms is the content of the intervention.
Again, control materials will be faxed from the patients'
community pharmacy. It should be noted here that "con-
trol," as we have defined it, is actually more rigorous than
the current standard of care; it might also be argued sim-
ply providing a medication profile would be sufficient in
an of itself to change practice, although a recent systematic
review concluded that this would not be the case [2].
Study setting
Capital Health (Edmonton, Alberta) is one of the largest
integrated health service delivery organizations in Can-
ada. It provides comprehensive health services for almost
one million people and has an annual budget of almost
two billion dollars Canadian. Primary care is delivered by
approximately 800 fee-for-service physicians. Community
dwelling patients with cardiovascular disease (either HF
or IHD) will be recruited from a convenience sample of 40
different community pharmacies, some of which have
previously participated in pharmacist-based research
studies. It should be noted that, at the time of study
design, none of these pharmacies were electronically
linked to either physicians' practice records or any form of
patients' medical charts.
Subjects
Involvement of primary care physicians has already been
described, and we potentially will be able to draw subjects
from the population-base of all fee-for-service physicians
in the entire region. Patients (and their prescribing physi-
cians) will be identified by community pharmacists from
lists obtained from their computerized dispensing
records. Patients with a prescription for a "marker" medi-
cation (a loop diuretic for the proxy diagnosis of HF; a
short acting nitrate for the proxy diagnosis of IHD) who
are not currently taking the respective study medications
of interest will be notified by their own pharmacist about
the study and informed that (with their permission) a
member of the research team will contact them with more
information about the study. A research assistant (phar-
macist) will then initiate telephone contact once potential
eligibility has been determined, and obtain verbal consent
from eligible patients to access their pharmacy records
twice (study entry and 6-month followup) for the pur-
poses of the study. It should be noted that these patient's
pharmacists, providing routine services in the commu-
nity, already have access to their pharmacy records. Spe-
cific criteria for inclusion and exclusion include the
following:
Inclusion criteria
Patients with HF or IHD who are not currently taking the
study medications of interest (ACE inhibitors/angiotensin
receptor blockers for HF or statins for IHD), and whose
primary care physician of record is part of the study. For
patients who happen to be eligible for both HF and for
IHD, only one condition will be selected at random.
Exclusion criteria
Patients who decline enrollment, or who are unable or
unwilling to give informed consent, or who have previ-
ously taken the study medications according to dispens-
ing records, or who have a documented allergy or
intolerance to study medications according to pharmacist
records, or who are in long-term care facilities or institu-
tions, or who do not confirm on the basis of self-report
that they have a diagnosis of either HF or IHD, or whose
primary care physician has already contributed 5 patients
to the study.
Allocation to experimental arms
Simple randomization will occur at the level of the pri-
mary care physician, before patient recruitment and
enrollment begins, using a computer-generated sequence
with allocation concealment. Each participating physician
will be randomly allocated to intervention or control arm
for HF; physicians allocated to intervention for HF will be
automatically assigned to the control arm for IHD, and
vice versa. This design prevents "contamination" within
an individual physicians' practice (e.g., having one inter-
vention HF patient and one control HF patient), while
simultaneously increasing study efficiency (i.e., physi-
cians can contribute patients to both the HF and IHD
arms of the study, thus potentially reducing the overall
number of physicians required). Furthermore, no one
physician will be permitted to contribute more than 5
patients to the study, to minimize any issues related to the
potential for physician-level clustering of study outcomes
[23,24].BMC Cardiovascular Disorders 2005, 5:17 http://www.biomedcentral.com/1471-2261/5/17
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That said, this might be considered a form of "cluster" ran-
domization [2,23,24]. However, on a population-wide
basis we anticipate that most regional physicians will con-
tribute no patients, and the majority of physicians will
contribute no more than 1 study patient. This has been
the case in previous studies we have recently undertaken
using similar recruitment and allocation methods
[19,25]. Furthermore, by our study design, no physician
will be able to contribute more than 5 patients to the
study as a whole. Therefore, the "design effect" should be
negligible, particularly since previous studies have dem-
onstrated that important cluster effects do not come into
play until the physician-to-patient ratio exceeds 1-to-5,
and we expect our ratio to be close to 1-to-1; thus, all sam-
ple size and analytic considerations will be based on the
patient as the unit of analysis and the unit of causal infer-
ence [23-25].
Outcome measures
The primary outcome measure will be the "improvement"
of prescribing for efficacious therapies in patients with a
chronic cardiovascular disease within 6 months of the
intervention. By study design, none of the study patients
will be taking the medications of interest. For HF, starting
any ACE inhibitor or angiotensin receptor blocker will be
considered a positive outcome. For IHD, starting any sta-
tin will be considered a positive outcome. For the primary
outcome all positive study-related medication changes
will be pooled for an overall estimate of effect, compared
with usual care controls.
The main secondary outcomes will be condition-specific
"improvement" in prescribing after 6 months. In addi-
tion, we will attempt to assess optimization of dosage for
each of the medications prescribed (i.e., ACE inhibitors or
angiotensin receptor blockers and statins). We will also
evaluate patient adherence (using prescription refill rates
based on dispensing records) and examine the potential
influence of age and sex on outcomes.
Study procedures and data collection
The primary source of data for the study will be the
patient-level medication profiles generated at each com-
munity pharmacy. All data will be collected by a research
assistant traveling to each pharmacy. Data will be col-
lected using a standardized abstraction instrument. Only
data without unique personal identifiers, but with a
unique study ID# (and therefore anonymized), will be
entered into a secure database housed at the EPICORE
Centre, University of Alberta. Investigators will be blinded
to physician- and patient-level unique identifiers and
investigators and study patients will be masked to alloca-
tion status. Primary care physicians themselves cannot be
blinded to allocation status. Follow-up data collection is
scheduled at 6-months, again based on patient-level med-
ication profiles generated by participating pharmacists,
and follow-up data will be collected without knowledge
of allocation status in an independent and blinded fash-
ion. All statistical analyses will be conducted by an inde-
pendent statistician also masked to allocation status.
Covariates that will be collected include age, sex, and self-
reported medical diagnoses. Using medication profiles,
we will also be able to generate a previously validated
measure of comorbidity, the Chronic Disease Score. This
measure has been previously demonstrated to provide
valid and reliable risk adjustment for comorbidity or case-
mix, and it is able to predict long-term morbidity, hospi-
talization, mortality, and health care utilization [26].
The time period chosen for outcome assessment (6-
months) was selected as the vast majority of HF patients
(over 80% [10]) are seen at least every 6 months and a
poll of general internal medicine specialists and cardiolo-
gists at the University of Alberta confirmed that most IHD
patients are also seen within this same time period. Data
collation, quality assurance, and statistical analyses will
be carried out at the EPICORE Centre.
Statistical analyses
Although the physician will be the unit of allocation, the
patient is the unit of analysis and causal inference. This is
justified by the anticipated small design effect, and the fact
we expect that the outcomes for individual patients to be
clinically and statistically independent of each other –
because each intervention is itself both patient- and con-
dition-specific. The main analysis will be a comparison of
the proportion of all patients who successfully achieve the
primary outcome ("improved" prescribing of efficacious
therapies, as described above) at 6-months. This will be
tested using the chi square statistic. There will be no
planned interim analyses, and we will consider a p-value
<0.05 to be statistically significant. Secondary analyses
will compare the proportions of patients who successfully
achieve the primary outcome in each of the two cardiovas-
cular conditions (HF and IHD), to determine whether
observed effects are consistent across different disease
states. Two prespecified subgroups (male vs. female and
age less than 70 years vs. 70 years of age and older) will
also be considered. Secondary outcomes will be studied in
an analogous fashion, and will be considered only explor-
atory in nature, and as such, comparisons will be made
without corrections for multiple testing.
In order to investigate what factors are associated with
changes in the primary outcome (our dependent binary
variable), and to control for the possibility of potential
imbalances in patient-level characteristics induced by our
randomization scheme, multivariable logistic regression
analyses will be used to examine those variables that areBMC Cardiovascular Disorders 2005, 5:17 http://www.biomedcentral.com/1471-2261/5/17
Page 6 of 8
(page number not for citation purposes)
deemed to be clinically important (i.e., age, sex, diabetes
status) or that differ statistically at a p-value <0.10
between experimental arms. In addition, to examine the
remote possibility of "cluster-associated" study design
effects, two secondary sensitivity analyses will be consid-
ered: first, the main analysis will be repeated using the
physician as the unit of analysis [2,23,24]; and second, the
aforementioned logistic regression models will be re-ana-
lyzed using generalized estimating equations to control
for the potential lack of statistical independence among
patients treated by the same study physician [2,23,24].
Sample size considerations
Using surveys of physicians and policy-makers, we deter-
mined that the "minimal" clinically important difference
for this particular intervention to be considered both use-
ful (and perhaps) fundable on an ongoing basis, was a
20% improvement over and above usual care. By design,
use of any of the study medications at baseline will be
zero. After 6 months, we assume no more than 10% of
control patients will have started a study medication.
Acknowledging that a 20% absolute increase in the pri-
mary outcome (starting a study medication, either an ACE
inhibitor or angiotensin receptor blocker [HF] or a statin
[IHD]) would be a clinically important effect size, setting
the α  error rate at 0.05 (2-sided), and the β  error at 0.20
(power 80%), a total sample size of 140 will be required.
Allowing for losses to follow-up, the ability to examine
each of the conditions separately, and the possibility of a
very small design effect associated with patient clustering,
the total sample size has been adjusted upwards to 160
patients.
Ethical considerations
The protocol and procedures as described have received
institutional approval from the Health Research Ethics
Board of the University of Alberta. In addition, any indi-
vidual physician or patient will have the opportunity to
withdraw from the study at any time, and none of the
investigators or analysts will have access to any physician-
identifiable or patient-identifiable data. The funding for
the study is from two peer-reviewed grants. The funding
sources (Alberta Heritage Foundation for Medical
Research and the Institute of Health Economics, Edmon-
ton, Alberta) had no role in the design, conduct, analysis,
interpretation, or reporting of the study and will not have
access to the data. Finally, it should be noted that the 5
opinion leaders received no compensation (financial or
otherwise) whatsoever for their participation in the study
or endorsement of the evidence summaries.
Discussion
Herein, we have reported the background, rationale, and
study protocol for a pragmatic cluster randomized con-
trolled trial of an intervention that will test the hypothesis
that opinion leader-generated and endorsed one page evi-
dence summaries that are patient-specific will be able to
improve the quality of cardiovascular medication pre-
scribing. The opinion leader literature is sparse at best,
and yet the potential role and educational influence of
these important physician champions is vastly underap-
preciated. To our knowledge, this will be the only rigorous
study of the "opinion leader hypothesis" undertaken out-
side the acute care or hospital setting. In addition, we will
be able to gather valuable data about the potential role for
community pharmacies and pharmacists in improving
the quality of care for patients with chronic diseases that
(by definition) require careful and longterm polyphar-
macy.
Perhaps a more ideal study could be undertaken in a more
hospitable setting, such as a large managed care organiza-
tion or a large academic medical centre – one that has a
captive population and where all health providers have
access to a universal electronic medical record that is
directly linked to pharmacy dispensing databases and
where there is potential for computerized decision sup-
port with the capacity to generate real time reminders and
prompts. Indeed, this has been tested in a randomized
trial for outpatients with chronic HF or chronic IHD (an
almost identical population in most respects to the one
we are enrolling), and it has been found wanting [27]. It
could be that information technology alone will be una-
ble to improve the quality of care if the treatment recom-
mendations are not first endorsed by local opinion
leaders. This possibility, as well as the fact that most com-
munity-based practices are years to decades away from
having clinically useful and integrated electronic health
information systems, will mean that the results of our
study will likely have broader implications than for just
the two conditions we chose to study.
Conclusion
If we are able to demonstrate that opinion leaders can
change clinical practice in the community, then larger
multi-centre studies of different conditions (e.g., control-
ler medications in asthma, antiresorptive therapies in
osteoporotic patients with fractures, antihypertensive
agents in people with diabetes) will need to be under-
taken.
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